Kerstin Hellwig
Overview
Explore the profile of Kerstin Hellwig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
174
Citations
3262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hellwig K, Magyari M, MacDonald T, Cesta C, Wergeland S, Leinonen M, et al.
Ther Adv Neurol Disord
. 2025 Jan;
18:17562864241310996.
PMID: 39872126
Background: Cladribine tablets are contraindicated during pregnancy; therefore, safety data on pregnancies exposed to this treatment are limited. CLEAR collects and describes pregnancy outcomes in this understudied population. Objectives: To...
2.
Schade P, Nguyen H, Steinle J, Hellwig K, Pelea T, Franken P, et al.
Ther Adv Neurol Disord
. 2025 Jan;
18:17562864241309806.
PMID: 39866752
Background: Complete vaccination coverage is recommended by multiple sclerosis (MS) societies for patients with multiple sclerosis (pwMS) to mitigate infection risks associated with disease-modifying therapies (DMTs). Objectives: To analyze vaccination...
3.
Bast N, Dost-Kovalsky K, Haben S, Friedmann N, Witt L, Oganowski T, et al.
Lancet Reg Health Eur
. 2025 Jan;
48():101137.
PMID: 39811788
Background: In recent decades, relapsing remitting multiple sclerosis (MS) became more treatable through new disease-modifying therapies (DMTs). Identifying safe treatments with minimal fetal risks for family planning is needed. Methods:...
4.
Witt L, Dost-Kovalsky K, Friedmann N, Bast N, Haben S, Oganowski T, et al.
Mult Scler
. 2025 Jan;
:13524585241307165.
PMID: 39757874
Background: In Europe, ofatumumab is approved for breastfeeding, but data on its transfer into breast milk and clinical experience are lacking. Objective: To analyze (1) health, development, and adverse events...
5.
Vukusic S, Bove R, Dobson R, McElrath T, Oreja-Guevara C, Pietrasanta C, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Dec;
12(1):e200349.
PMID: 39689270
Background And Objectives: Ocrelizumab labeling advises contraception for women during treatment and for 6-12 months thereafter. Because pregnancies may occur during this time, it is critical to understand pregnancy and...
6.
Merki-Feld G, Bove R, Haddad L, Hellwig K, Hillert J, Houtchens M, et al.
Eur J Contracept Reprod Health Care
. 2024 Dec;
:1-15.
PMID: 39676715
Purpose: Multiple sclerosis (MS) is often diagnosed in people of reproductive age. However, family planning counselling is not always integrated within MS care. Decisions on family planning can be further...
7.
Hefner S, Casaccia T, Hofstaetter E, Otto F, Hellwig K, Moser T
Neurol Clin Pract
. 2024 Nov;
15(1):e200410.
PMID: 39524100
Objectives: Anti-CD20 therapies are highly effective treatment options for patients with multiple sclerosis (MS), an inflammatory disorder of the CNS commonly affecting women of childbearing age. Anti-CD20 therapies are however...
8.
Witt L, Haben S, Dost-Kovalsky K, Friedmann N, Bast N, Oganowski T, et al.
Mult Scler
. 2024 Nov;
30(14):1775-1787.
PMID: 39503322
Background: Information on symptomatic therapy (ST) use in women of childbearing age with multiple sclerosis is sparse, and data on the impact of ST pregnancy exposure on pregnancy outcome are...
9.
Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Skuljec J, et al.
Neurology
. 2024 Oct;
103(9):e209888.
PMID: 39353149
Background And Objectives: Attack prevention is crucial in managing neuromyelitis optica spectrum disorders (NMOSDs). Eculizumab (ECU), an inhibitor of the terminal complement cascade, was highly effective in preventing attacks in...
10.
Scalfari A, Traboulsee A, Oh J, Airas L, Bittner S, Calabrese M, et al.
Ann Neurol
. 2024 Jul;
96(5):826-845.
PMID: 39051525
Despite therapeutic suppression of relapses, multiple sclerosis (MS) patients often experience subtle deterioration, which extends beyond the definition of "progression independent of relapsing activity." We propose the concept of smouldering-associated-worsening...